Clinical effectiveness and safety of edoxaban in obese patients - Results of the prospective Dresden NOAC Registry (NCT01588119)

Thromb Res. 2023 Aug:228:134-136. doi: 10.1016/j.thromres.2023.05.026. Epub 2023 Jun 2.

Authors

Luise Tittl¹, Christina Köhler¹, Sandra Marten¹, Christiane Naue¹, Kristina Fache¹, Laura Stannek¹, Thomas Schreier¹, Jan Beyer-Westendorf²

Affiliations

¹ Thrombosis Research Department of Medicine I, Division Haematology, University Hospital "Carl Gustav Carus", Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.
² Thrombosis Research Department of Medicine I, Division Haematology, University Hospital "Carl Gustav Carus", Technical University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Electronic address: jan.beyer@uniklinikum-dresden.de.

PMID: 37327528
DOI: 10.1016/j.thromres.2023.05.026

No abstract available

Keywords: Anticoagulants; Bleeding; Body mass index; Cardiovascular events; Obesity.

Publication types

Letter

MeSH terms

Administration, Oral
Anticoagulants / therapeutic use
Atrial Fibrillation* / drug therapy
Factor Xa Inhibitors / adverse effects
Humans
Obesity / complications
Obesity / drug therapy
Prospective Studies
Registries
Stroke* / drug therapy
Treatment Outcome

Substances

edoxaban
Anticoagulants
Factor Xa Inhibitors